REG - Polarean Imaging PLC - Korean distributor agreement with DK Healthcare

Polarean ImagingAnnouncement

24/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251124:nRSX6022Ia&default-theme=true

RNS Number : 6022I  Polarean Imaging PLC  24 November 2025

 

Polarean Imaging plc

("Polarean" or the "Company")

 

Korean distributor agreement with DK Healthcare in South Korea

Expanding commercial reach and advancing lung imaging innovation in
Asia-Pacific

 

Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging
technology leader in advanced Magnetic Resonance Imaging ("MRI") of lung
function, announces it has signed an exclusive distribution agreement with DK
Healthcare Co., Ltd. ("DK Healthcare") for the distribution of Polarean's
Xenon MRI platform in South Korea.

 

This agreement represents Polarean's second international distribution
partnership, strengthening the Company's commercial presence across the
Asia-Pacific region. Through this partnership, Polarean is strategically
positioning its innovative Xenon MRI platform for entry into one of the
world's most advanced medical imaging markets. The Company will collaborate
with DK Healthcare to obtain the necessary regulatory clearances ahead of
commercial launch in South Korea.

 

DK was founded in 1986 and is headquartered in Seoul. They are a leading
provider of diagnostic radiology systems and imaging technologies in Korea,
and DK Healthcare is one of the affiliates of DK. Through long-standing
partnerships with global medical device manufacturers, DK Healthcare has built
a reputation for delivering cutting-edge imaging solutions, along with
comprehensive technical, clinical, and maintenance support.

 

Christopher von Jako, Ph.D., CEO of Polarean, said: "We are delighted to
partner with DK Healthcare, one of South Korea's most respected medical
imaging distributors, to expand access to our Xenon MRI platform. South
Korea's strong emphasis on early detection and precision medicine makes it an
ideal growth market, and this agreement accelerates our dual-track strategy to
grow internationally through high-quality regional partners while our U.S.
team continues to drive adoption domestically."

 

Joonhyuk Lee, CEO of DK Healthcare, said: "We are excited to introduce
Polarean's Xenon MRI technology to Korea's leading hospitals and imaging
centers. This platform offers clinicians a new dimension in lung function
assessment by enabling visualisation of ventilation and gas-exchange that was
previously impossible with conventional imaging. We believe Xenon MRI will
play a vital role in transforming respiratory care in South Korea through
enhancing early detection and outcomes for patients with lung cancer, COPD and
beyond."

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014, as it forms part of domestic law by virtue of the
European Union (Withdrawal) Act 2018.

 

Enquiries:

 

 Polarean Imaging plc                                                  www.polarean.com / www.polarean-ir.com (http://www.polarean-ir.com)
 Christopher von Jako, Ph.D., Chief Executive Officer                  Via Walbrook PR
 Charles Osborne, Chief Financial Officer

 Stifel (NOMAD and Sole Corporate Broker)                                                       +44 (0)20 7710 7600
 Nicholas Moore / Fred Walsh / Brough Ransom  / Ben Good

 Walbrook PR              Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
 Anna Dunphy/ Paul McManus / Marcus Ulker            Mob: +44 (0)7876741001 / +44 (0) 7980541893 / +44 (0)7867984 082

 

About Polarean

Polarean is a revenue-generating medical imaging technology company
revolutionising pulmonary medicine through direct visualisation of lung
function by introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern solutions
to accurately assess lung function. The Company strives to optimise lung
health and prevent avoidable loss by illuminating hidden disease, addressing
the global unmet medical needs of more than 500 million patients worldwide
suffering from chronic respiratory disease. Polarean is a leader in the field
of hyperpolarisation science and has successfully developed the first and only
hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now
FDA-approved in the United States. Polarean is dedicated to researching,
developing, and commercialising innovative imaging solutions with its
non-invasive and radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary Xenon gas
blend, gas hyperpolarisation system, as well as software and accessories,
facilitating fully integrated modern respiratory imaging operations. Founded
in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its XENOVIEW
MRI technology platform.

 

For the latest news and information about Polarean, please visit
www.polarean.com (http://www.polarean.com) .

 

XENOVIEW® IMPORTANT SAFETY INFORMATION

 

Indication

XENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarised
contrast agent indicated for use with magnetic resonance imaging (MRI) for
evaluation of lung ventilation in adults and pediatric patients aged 6 years
and older.

 

Limitations of Use

XENOVIEW has not been evaluated for use with lung perfusion imaging.

 

CONTRAINDICATIONS

None.

 

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen
administered simultaneously with XENOVIEW inhalation can cause degradation of
image quality. For patients on supplemental oxygen, withhold oxygen inhalation
for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation
immediately following the imaging breath hold.

 

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may
cause transient hypoxemia in susceptible patients. Monitor all patients for
oxygen desaturation and symptoms of hypoxemia and treat as clinically
indicated.

 

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient)
in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse
Reactions in Pediatric and Adolescent Patients: In published literature in
pediatric patients aged 6 to 18, transient adverse reactions were reported:
blood oxygen desaturation, heart rate elevation, numbness, tingling,
dizziness, and euphoria. In at least one published study of pediatric patients
aged 6 to 18 years, transient decrease in SpO2% and transient increase in
heart rate was reported following hyperpolarized xenon Xe 129 administration.
XENOVIEW is not approved for use in pediatric patients less than 12 years of
age.

 

Please see full prescribing information at www.xenoview.net
(http://www.xenoview.net) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRKZMZMKMVGKZM



            Copyright 2019 Regulatory News Service, all rights reserved